- Home
- FBNC vs SUPN Comparison
FBNC vs SUPN Comparison
Compare FBNC & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBNC
- SUPN
- Stock Information
- Founded
- FBNC 1934
- SUPN 2005
- Country
- FBNC United States
- SUPN United States
- Employees
- FBNC N/A
- SUPN N/A
- Industry
- FBNC Major Banks
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- FBNC Finance
- SUPN Health Care
- Exchange
- FBNC Nasdaq
- SUPN Nasdaq
- Market Cap
- FBNC 1.7B
- SUPN 1.9B
- IPO Year
- FBNC N/A
- SUPN 2012
- Fundamental
- Price
- FBNC $41.73
- SUPN $32.02
- Analyst Decision
- FBNC Buy
- SUPN Hold
- Analyst Count
- FBNC 2
- SUPN 1
- Target Price
- FBNC $38.50
- SUPN $36.00
- AVG Volume (30 Days)
- FBNC 178.5K
- SUPN 405.0K
- Earning Date
- FBNC 10-23-2024
- SUPN 11-06-2024
- Dividend Yield
- FBNC 2.12%
- SUPN N/A
- EPS Growth
- FBNC N/A
- SUPN N/A
- EPS
- FBNC 2.75
- SUPN 0.08
- Revenue
- FBNC $380,101,000.00
- SUPN $630,163,000.00
- Revenue This Year
- FBNC N/A
- SUPN $4.01
- Revenue Next Year
- FBNC $5.32
- SUPN $0.10
- P/E Ratio
- FBNC $15.11
- SUPN $337.64
- Revenue Growth
- FBNC 0.28
- SUPN N/A
- 52 Week Low
- FBNC $26.00
- SUPN $21.99
- 52 Week High
- FBNC $45.41
- SUPN $35.44
- Technical
- Relative Strength Index (RSI)
- FBNC 51.47
- SUPN 50.67
- Support Level
- FBNC $40.11
- SUPN $29.74
- Resistance Level
- FBNC $41.99
- SUPN $32.32
- Average True Range (ATR)
- FBNC 1.18
- SUPN 0.80
- MACD
- FBNC -0.25
- SUPN 0.09
- Stochastic Oscillator
- FBNC 36.12
- SUPN 77.82
About FBNC First Bancorp
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing, and investment advisory services.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.